Actively Recruiting
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Led by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Updated on 2026-04-07
172
Participants Needed
24
Research Sites
400 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
CONDITIONS
Official Title
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female participants with histologically or cytologically confirmed FIGO Stage III/IV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal carcinoma
- For Part 1, participants must have received 1 or 2 prior therapies in the advanced/metastatic setting including at least one containing cisplatin or carboplatin
- Disease must be platinum resistant (progression-free interval less than 6 months) or platinum refractory
- For Part 2 Dose Escalation, subjects must have received 6 cycles of platinum-based doublet chemotherapy as their most recent therapy in 1L or 2L setting
- For Part 2 Dose Escalation, response to prior platinum therapy includes complete response, partial response, or stable disease
- For Part 2 Dose Expansion, subjects must have at least 4 cycles of platinum-based chemotherapy in 2L with complete response, partial response, or stable disease
- Subjects must have progressed while on a PARP inhibitor for 1L maintenance
- Adequate hematologic and organ function
You will not qualify if you...
- Diagnosis of abdominal adenocarcinoma of unknown origin or borderline ovarian tumor
- Presence of carcinosarcomas, even with a serous component
- Serious illness or medical conditions that could interfere with study participation
- Active, uncontrolled, or metastatic second malignancies requiring therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 24 locations
1
Site 0264
Aurora, Colorado, United States, 80045
Actively Recruiting
2
Site 0104
Boston, Massachusetts, United States, 02215
Actively Recruiting
3
Site 0111
St Louis, Missouri, United States, 53110
Actively Recruiting
4
Site 0173
New York, New York, United States, 10029
Actively Recruiting
5
Site 0259
Durham, North Carolina, United States, 27710
Actively Recruiting
6
Site 0191
Providence, Rhode Island, United States, 02905
Actively Recruiting
7
Site 0196
Nashville, Tennessee, United States, 37203
Completed
8
Site 0103
Houston, Texas, United States, 77030
Actively Recruiting
9
Site 2707
South Brisbane, Queensland, Australia, 4101
Completed
10
Site 2708
Sunshine Coast, Queensland, Australia, 4556
Completed
11
Site 2709
Adelaide, South Australia, Australia, 5000
Completed
12
Site 2716
Melbourne, Victoria, Australia, 3121
Actively Recruiting
13
Site 2706
Melbourne, Victoria, Australia, 3144
Actively Recruiting
14
Site 2705
Nedlands, Western Australia, Australia, 6009
Actively Recruiting
15
Site 1001
Banja Luka, Bosnia and Herzegovina, 78000
Completed
16
Site 1002
Sarajevo, Bosnia and Herzegovina, 71000
Completed
17
Site 1003
Tuzla, Bosnia and Herzegovina, 75000
Completed
18
Site 1202
Panagyurishte, Bulgaria, 4500
Completed
19
Site 1201
Sofia, Bulgaria, 1632
Completed
20
Site 1401
Tbilisi, Georgia, 0112
Completed
21
Site 1902
Belgrade, Serbia, 11080
Completed
22
Site 2901
Busan, South Korea
Completed
23
Site 2903
Seoul, South Korea, 03080
Completed
24
Site 2904
Seoul, South Korea, 05505
Completed
Research Team
K
K-Group, Beta, Inc., a subsidiary of Zentalis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here